Tab. V.

Efficacy trials and surveillance studies of the effectiveness of acellular pertussis vaccines (aPs).

Author or Country	N. antigen components	Efficacy (%) or effectiveness (incidence)
Greco [7]	3	84%
Gustafsson [8]	2*; 5	59%*; 85%
Simondon [63]	2	85%
Trollfors [75]	1	71%
Sweden [65]	1, 2, 3, 5	From > 100 cases/100,000 to < 10 cases/100,000 residents
Denmark [66]	1	From > 100 cases/100,000 to < 10 cases/100,000 residents
EU/EEA countries [19]	1, 2, 3, 5	From > 100 cases/100,000 to < 10 cases/100,000 residents
Non-EU/EEA countries: USA [67], Canada [68], Japan [56]	1, 2, 3, 5	From > 100 cases/100,000 to < 10 cases/100,000 residents

*; 2-component vaccine not registered and never used in national vaccination programs.